Μολδαβία -
Ρουμανικά -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
voltaren forte 23 2 mg g gel 23,2 mg
glaxosmithkline consumer healthcare srl - diclofenacum diethylaminum - gel - 23,2 mg
Ευρωπαϊκή Ένωση -
Ρουμανικά -
EMA (European Medicines Agency)
budesonide/formoterol teva pharma b.v.
teva pharma b.v. - budesonide, formoterol - astm - medicamente pentru afecțiuni obstructive ale căilor respiratorii, - budesonidă / formoterol teva pharma b. este indicat numai la adulți cu vârsta de 18 ani și peste. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
Ευρωπαϊκή Ένωση -
Ρουμανικά -
EMA (European Medicines Agency)
aflunov
seqirus s.r.l. - antigene de suprafață ale virusului gripal (hemaglutinină și neuraminidază) din tulpina: a/turkey/turkey/1/05 (h5n1) ca tulpină (nibrg-23) - influenza, human; immunization; disease outbreaks - vaccinuri - imunizarea activă împotriva subtipului h5n1 al virusului gripal-a. această indicație se bazează pe imunogenitate date de la subiecți sănătoși cu vârsta de 18 ani, începând de la administrarea a două doze de vaccin conținând o/turkey/turkey/1/05 (h5n1) ca tulpină. aflunov ar trebui să fie utilizate în conformitate cu recomandările oficiale.
Ρουμανία -
Ρουμανικά -
ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)
metoprolol succinat teva 23,75 mg
teva pharmaceuticals s.r.l. - metoprololum - compr. elib. prel. - 23,75mg - agenti betablocanti betablocante selective
Μολδαβία -
Ρουμανικά -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
pneumovax 23 pneumococcal polysaccharide vaccine 25 mcg/0,5 ml (1 doză) soluţie injectabilă
merck sharp & dohme idea gmbh - vaccin pneumococic - soluţie injectabilă - 25 mcg/0,5 ml (1 doză)
Μολδαβία -
Ρουμανικά -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
pneumovax 23 25 mcg/0,5 ml (1 doză) soluţie injectabilă
merck sharp & dohme idea gmbh - vaccin pneumococic - soluţie injectabilă - 25 mcg/0,5 ml (1 doză)
Ευρωπαϊκή Ένωση -
Ρουμανικά -
EMA (European Medicines Agency)
qdenga
takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - vaccinuri - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.
Ευρωπαϊκή Ένωση -
Ρουμανικά -
EMA (European Medicines Agency)
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agenți antineoplazici - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
Ευρωπαϊκή Ένωση -
Ρουμανικά -
EMA (European Medicines Agency)
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - sânii neoplasme - agenți antineoplazici - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.